Evonik is launching a functional, ready-to-fill oral capsule designed for use in preclinical trials. EUDRACAP preclinic enteric is a very small size 9h (5.1 mm), technical-grade capsule suitable for passing through the gastrointestinal tract of preclinical animal models.

The enteric-coated capsule enables pharmaceutical companies to optimize drug development by reducing cost, time, and variables during preclinical trials. Companies can also move seamlessly from preclinical to clinical and commercial stages using the EUDRACAP platform.

EUDRACAP preclinic enteric is the latest addition to Evonik’s EUDRACAP platform of easy-to-handle capsules.

The platform leverages the established EUDRAGIT® functional coatings for optimized release profiles of oral drug products. With its long-standing experience in functional excipients, formulation and applications services, Evonik provides System Solutions to its customers. System Solutions are multi-component offerings across products, technologies and services that provide customers with end-to-end development and manufacturing services for complex drug products. It is the vision of Evonik’s life sciences division, Nutrition & Care, to increase its share of System Solutions from 20 to 70 percent by 2032.

“Every extra step in the drug development process costs time and adds risk. The latest addition to our EUDRACAP platform is an easy way for our customers to reduce complexity and streamline the whole development process. We look forward to seeing the positive impact in the industry and patients it serves,” said Axel Schroeder, head of Global Business Segment Oral Drug Delivery Solutions at Evonik Health Care.

Preclinical trials are a cost-effective way to ensure that only the most promising drugs move forward to clinical trials, ultimately leading to the development of safe and effective drugs for patients. The gastrointestinal tract (GIT) conditions of animals used in preclinical trials have a significant impact on targeted drug delivery, as does the size of the capsules.